MOLECULAR PROFILE AND ANTI-TUMOR ACTIVITY IN NON-SMALL CELL LUNG CANCER (NSCLC) PATIENTS (PTS) IN A PHASE 1 STUDY OF CABOZANTINIB (XL184) IN JAPAN

被引：0
作者：
Nokihara, H. [1 ]
Yamamoto, N. [1 ]
Nakamichi, S. [1 ]
Wakui, H. [1 ]
Yamada, Y.
Frye, J. [2 ]
Decillis, A. [2 ,3 ]
Tamura, T. [4 ]
机构：
[1] Natl Canc Ctr, Div Thorac Oncol, Tokyo, Japan
[2] Exelixis Inc, Med Affairs, San Francisco, CA USA
[3] Exelixis Inc, Clin Dev, San Francisco, CA USA
[4] Natl Canc Ctr, Div Internal Med & Thorac Oncol, Tokyo, Japan
来源：
ANNALS OF ONCOLOGY | 2012年 / 23卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：174 / 174
页数：1
相关论文
共 50 条
  • [21] A phase II study of atezolizumab as neoadjuvant and adjuvant therapy in patients (pts) with resectable non-small cell lung cancer (NSCLC).
    Owen, Dwight Hall
    Bunn, Paul A.
    Johnson, Bruce E.
    Kwiatkowski, David J.
    Kris, Mark G.
    Wistuba, Ignacio Ivan
    Gandhi, Mayank
    Phan, See
    Shames, David S.
    Schulze, Katja
    Yu, Wei
    Aisner, Dara
    Chaft, Jamie E.
    Garon, Edward B.
    Lee, Jay M.
    Minna, John D.
    Rusch, Valerie W.
    Reckamp, Karen L.
    Wozniak, Antoinette J.
    Carbone, David P.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [22] Anlotinib enhances the anti-tumor activity of osimertinib in patients with non-small cell lung cancer by reversing drug resistance
    Hua, Xin
    Wu, Xiaodi
    Lv, Liting
    Gu, Yanli
    Zhu, Suhua
    Liu, Xin
    Lv, Tangfeng
    Song, Yong
    TRANSLATIONAL LUNG CANCER RESEARCH, 2025, 14 (01) : 40 - 57
  • [23] Anti-tumor activity of autologous GM-CSF gene-modified tumor cell vaccines (GVAX®) in non-small cell lung cancer (NSCLC)
    Hege, K
    Sterman, D
    Jablons, D
    Smith, J
    Fox, B
    Woo, EY
    Lin, A
    Borellini, F
    Jalali, S
    Maples, P
    Nemunaitis, J
    CANCER GENE THERAPY, 2001, 8 : S24 - S24
  • [24] Trends in demographics and survival for patients (pts) with advanced non-small cell lung cancer (NSCLC).
    Kubota, K.
    Masuhara, H.
    Hosoya, K.
    Yoh, K.
    Niho, S.
    Goto, K.
    Ohmatsu, H.
    Nishiwaki, Y.
    Saijo, N.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 392S - 392S
  • [25] Open-label phase I/II study evaluating the tolerability and anti-tumor activity of selinexor (SEL) and docetaxel (DTX) in non-small cell lung cancer (NSCLC)
    Zer, A.
    Dudnik, J.
    Shamai, S.
    Gottfried, M.
    Zick, A.
    Shai, A.
    Kutiel, T. Shentzer
    Netiv, E.
    Yang, F.
    Sharoni, S.
    Meng, C.
    Duic, P.
    Michel, D.
    Sbar, E.
    Shah, J.
    Kauffman, M. G.
    Shacham, S.
    Golan, T.
    ANNALS OF ONCOLOGY, 2021, 32 : S1019 - S1019
  • [26] A phase II study of XL647 in patients with non-small cell lung cancer (NSCLC) enriched for presence of EGFR mutations
    Rizvi, Naiyer
    Kris, Mark
    Miller, Vincent
    Krug, Lee
    Bekele, Saira
    Dowlati, Afshin
    Rowland, Kendrith
    Tonda, Margaret
    Mitchell, Benjamin
    Ruckdeschels, Jack
    Chaplen, Ruth
    Aggarwal, Neelesh
    Gadgeel, Shirish
    MOLECULAR CANCER THERAPEUTICS, 2007, 6 (12) : 3473S - 3473S
  • [27] Clinical trials of MPDL3280A (anti-PDL1) in patients (pts) with non-small cell lung cancer (NSCLC)
    Rizvi, Naiyer A.
    Chow, Laura Quan Man
    Dirix, Luc Yves
    Gettinger, Scott N.
    Gordon, Michael S.
    Kabbinavar, Fairooz F.
    Von Pawel, Joachim
    Sorla, Jean-Charles
    Chappey, Colombo
    Mokatrin, Ahmed
    Sandler, Alan
    Waterkamp, Daniel
    Spigel, David R.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [28] Immunological efficacy of anti-tumor dendritic cell vaccine application in patients with non-small cell lung cancer
    Gorbach, O.
    Khranovska, N.
    Skachkova, O.
    Inomistova, M.
    Sovenko, V.
    Ganul, A.
    Orel, V.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (04) : S37 - S38
  • [29] Pharmacokinetic (PK) profile of quisinostat in combination with gemcitabine and cisplatin in patients (pts) with non-small cell lung cancer (NSCLC) or paclitaxel and carboplatin in pts with NSCLC or epithelial ovarian cancer
    Fedyanin, M.
    Tjulandin, S.
    Cheporov, S.
    Vladimirov, V.
    Moiseenko, V.
    Orlov, S.
    Manikhas, G.
    Koryakova, A.
    Cakana, A.
    Phelps, C.
    Baranovsky, S.
    Azarova, V.
    Karavaeva, O.
    Vostokova, N.
    EUROPEAN JOURNAL OF CANCER, 2017, 72 : S96 - S96
  • [30] Phase II and pharmacogenetic study of docetaxel (D) and capecitabine (C) in chemonaive non-small cell lung cancer (NSCLC) patients (pts)
    Lustberg, M. B.
    Bekaii-Saab, T. S.
    Diasio, R.
    Ezzeldin, H.
    Starrett, S. L.
    Otterson, G. A.
    Villalona, M. A.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
12345